A novel CD147 inhibitor, SP-8356, reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation

Kisoo Pahk, Hyojin Noh, Chanmin Joung, Mi Jang, Hwa Young Song, Kyung Won Kim, Kihoon Han, Jong Ik Hwang, Sungeun Kim, Won Ki Kim

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)


Background: Neointimal hyperplasia and its related arterial stiffness are the crucial pathophysiological features in atherosclerosis and in-stent restenosis. Cluster of differentiation 147 (CD147), a member of the immunoglobulin super family that induces the expression of matrix metalloproteinase-9 (MMP-9) by dimerization, may play important roles in neointimal hyperplasia and may therefore be an effective target for the treatment of this condition. Here, we investigated whether a novel CD147 inhibitor SP-8356 ((1S,5R)-4-(3,4-dihydroxy-5-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one) reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation. Methods: Neointimal hyperplasia was induced in Sprague-Dawley rats by partial ligation of the right carotid artery combined with a high fat diet and vitamin D injection. Rats were subdivided into vehicle, SP-8356 (50 mg/kg), and rosuvastatin (10 mg/kg) groups. The drugs were administrated via intraperitoneal injections for 4 weeks. The elasticity of blood vessels was assessed by measuring pulse wave velocity using Doppler ultrasonography before sacrifice. Histomolecular analysis was carried out on harvested carotid arteries. Results: SP-8356 significantly reduced MMP activity by inhibiting CD147 dimerization. SP-8356 reduced neointimal hyperplasia and prevented the deterioration of vascular elasticity. SP-8356 had a greater inhibitory effect on neointimal hyperplasia than did rosuvastatin. Furthermore, rosuvastatin did not improve vascular elasticity. SP-8356 increased the expression of smooth muscle myosin heavy chain (SM-MHC), but decreased the expression of collagen type III and MMP-9 in the neointimal region. In contrast to SP-8356, rosuvastatin did not alter the expression of SM-MHC or MMP-9. Conclusions: The ability of SP-8356 to reduce neointimal hyperplasia and improve arterial stiffness in affected carotid artery suggests that SP-8356 could be a promising therapeutic drug for vascular remodeling disorders involving neointimal hyperplasia and arterial stiffness.

Original languageEnglish
Article number274
JournalJournal of Translational Medicine
Issue number1
Publication statusPublished - 2019 Aug 20

Bibliographical note

Funding Information:
This work was supported by a Grant from the Basic Science Research Program [NRF‑2015R1A2A01004202, NRF‑2018R1A2A2A05018319] through the National Research Foundation of Korea (NRF) funded by the Ministry of Sci‑ ence, ICT & Future Planning, Republic of Korea. This work was also supported by the Technology Innovation Program (10078367, Development of New Drug for Intractable Cardio‑Cerebro Vascular Diseases through Inhibition of CD147/EMMPRIN) funded by the Ministry of Trade, Industry & Energy (MOTIE), Republic of Korea.

Publisher Copyright:
© 2019 The Author(s).


  • Arterial stiffness
  • Atherosclerosis
  • CD147
  • MMP-9
  • Matrix metalloproteinase
  • Neointimal hyperplasia
  • Vascular smooth muscle cell

ASJC Scopus subject areas

  • General Biochemistry,Genetics and Molecular Biology


Dive into the research topics of 'A novel CD147 inhibitor, SP-8356, reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation'. Together they form a unique fingerprint.

Cite this